Esperion Therapeutics Stock Discussion

$Esperion Therapeutics (ESPR.US)$
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
Positive
Total revenue increased 186% year-over-year to $73.8 million
U.S. net product revenue grew 39% to $28.3 million
Monetized European royalties for $304.7 million, enhancing financial flexibility
Expanded payer coverage, with over 80% updating utilization management criteria
Increased preferred commercial coverage to 92% and Medicare preferred coverage to over 50%
Rec...

$Esperion Therapeutics (ESPR.US)$
Hurry Up！Go ahead！🚀🚀🚀🏆🏆🏆

$Esperion Therapeutics (ESPR.US)$
waiting for 12/8，good price！

$Esperion Therapeutics (ESPR.US)$
every time 2-3，improve very quickly！

$Esperion Therapeutics (ESPR.US)$
Will be a very good one！

$Esperion Therapeutics (ESPR.US)$ break 2.64 and move

$Esperion Therapeutics (ESPR.US)$
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-app...

$Esperion Therapeutics (ESPR.US)$ keep moving